AstraZeneca releases US COVID-19 vaccine trial results: 5 things to know

AstraZeneca's COVID-19 vaccine was 74 percent effective at preventing symptomatic disease in its phase 3 U.S. clinical trial, according to a study released Sept. 29 in The New England Journal of Medicine.